
Grounded in science, guided by patients.
About Mesenkia
Mesenkia is a pre-clinical company developing the next-generation biological drug candidates designed to treat the aggressive brain tumor glioblastoma. Mesenkia is founded on world leading science from Uppsala University and the University of Tokyo originating from decades of collaborations dedicated to finding the root cause for tumor pathogenesis. The founders identified HVEM signaling as crucial for glioblastoma pathogenesis and developed a technology for disrupting the pathway.
Our Science
200,000+
patients affected each year
~15 mo
median survival today
$5.7B
market by 2033
2030
first-in-Human targeted
News
Meet our CEO and learn more about our groundbreaking antibody technology and investment opportunity in one of our four investor ...
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and Mesenkia Therapeutics announced today that the companies have signed a research collaboration ...
Researchers have identified HVEM as a promising therapeutic target in mesenchymal glioblastoma...
Kohei Miyazono has been elected as a new member to the Academy’s class for medical sciences at the royal ...
